{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Peptic+Ulcer+Disease&page=2",
    "query": {
      "condition": "Peptic Ulcer Disease",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Peptic+Ulcer+Disease&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T18:11:22.437Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00212225",
      "title": "Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Helicobacter Infections",
        "Gastritis",
        "Peptic Ulcer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 755,
      "start_date": "1997-10",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2010-01-13",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Atlanta, Georgia • Cleveland, Ohio",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00212225"
    },
    {
      "nct_id": "NCT00284908",
      "title": "Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophagitis",
        "Gastroesophageal Reflux",
        "Stomach Ulcer",
        "Duodenal Ulcer"
      ],
      "interventions": [
        {
          "name": "S-Tenatoprazole-Na (STU-Na)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "STEBA France",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2006-09",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2008-03-24",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00284908"
    },
    {
      "nct_id": "NCT03123835",
      "title": "Outcome Analysis of POEM and Endoluminal Therapies",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Achalasia",
        "Gastric Fistula",
        "Weight Gain After Primary Weight Loss Surgery",
        "Marginal Ulcer",
        "Stenoses",
        "Gastric Nec"
      ],
      "interventions": [
        {
          "name": "Endoscopic Intervention",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 500,
      "start_date": "2016-03",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03123835"
    },
    {
      "nct_id": "NCT00527904",
      "title": "A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Ulcer"
      ],
      "interventions": [
        {
          "name": "PN400 (VIMOVO)",
          "type": "DRUG"
        },
        {
          "name": "PN 400 (VIMOVO)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "POZEN",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 239,
      "start_date": "2007-03",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2010-08-31",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00527904"
    },
    {
      "nct_id": "NCT01204476",
      "title": "Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrin-Producing Neuroendocrine Tumor",
        "Lung Carcinoid Tumor",
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Pancreatic Glucagonoma",
        "Pancreatic Insulinoma",
        "Pancreatic Polypeptide Tumor",
        "Paraganglioma",
        "Recurrent Digestive System Neuroendocrine Tumor G1",
        "Recurrent Merkel Cell Carcinoma",
        "Recurrent Pancreatic Neuroendocrine Carcinoma",
        "Regional Digestive System Neuroendocrine Tumor G1",
        "Somatostatin-Producing Neuroendocrine Tumor",
        "Stage III Merkel Cell Carcinoma",
        "Stage IV Merkel Cell Carcinoma",
        "Thyroid Gland Medullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Octreotide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-07-15",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204476"
    },
    {
      "nct_id": "NCT03060733",
      "title": "Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Helicobacter Pylori Infection",
        "Gastric Ulcer",
        "Nausea",
        "Abdominal Pain",
        "Weight Loss",
        "Stomach Ulcer",
        "Loss of Appetite",
        "Bloating"
      ],
      "interventions": [
        {
          "name": "Post-Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "DiaSorin Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2017-02-14",
      "completion_date": "2018-05-14",
      "has_results": false,
      "last_update_posted_date": "2019-02-07",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 4,
      "location_summary": "Mission Hills, California • Great Neck, New York • Mentor, Ohio + 1 more",
      "locations": [
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Mentor",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03060733"
    },
    {
      "nct_id": "NCT05799105",
      "title": "OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Marginal Ulcer"
      ],
      "interventions": [
        {
          "name": "Omeprazole 40 milligrams",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stephen Firkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 122,
      "start_date": "2023-03-14",
      "completion_date": "2027-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05799105"
    },
    {
      "nct_id": "NCT05085405",
      "title": "Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Upper Gastrointestinal Bleeding"
      ],
      "interventions": [
        {
          "name": "Clinician notification",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Notification with Nurse Facilitation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Notification / Patient Activation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Notification with Nurse Facilitation / Patient Activation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2021-10-11",
      "completion_date": "2022-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05085405"
    },
    {
      "nct_id": "NCT00579410",
      "title": "Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Esophagitis",
        "Inflammation",
        "Gastritis",
        "Abdominal Pain",
        "Heartburn"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2004-05",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2011-03-22",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00579410"
    },
    {
      "nct_id": "NCT00869050",
      "title": "Capecitabine and Temozolomide for Neuroendocrine Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 41,
      "start_date": "2005-08",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-07-25",
      "last_synced_at": "2026-06-10T18:11:22.437Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00869050"
    }
  ]
}